DiaMedica Therapeutics (DMAC) Stock: Buy, Sell, or Hold?
DMAC - DiaMedica Therapeutics Inc. Common Stock
$8.72
0.09 (1.04%)
▲
5d:
+15.19%
30d:
+11.37%
90d:
+29.38%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
15d
Get Alerted When DMAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DMAC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DMAC shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: DMAC is currently trading at $8.72, which is considered extended relative to its 30-day fair value range of $7.52 to $8.49.
Technical Outlook: Technically, DMAC is in a strong uptrend. The price is approaching resistance at $8.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $15.50 (+77.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DMAC is in a strong uptrend. The price is approaching resistance at $8.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $15.50 (+77.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.52 -
$8.49
Company Quality Score
46/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
40.4%
All Signals
- BEARISH: Price extended above range
- BEARISH: Options expensive (IV 100th percentile)
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 77.8% below Wall St target ($15.50)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.52 -
$8.49
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.98
(34.1%)
Support & Resistance Levels
Support Level
$7.53
Resistance Level
$8.95
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.79
Wall Street Target
$15.50
(+77.8%)
Share & Embed Analysis
Last updated: October 26, 2026 12:22 AM ET
Data refreshes hourly during market hours. Next update: 1:22 AM
Data refreshes hourly during market hours. Next update: 1:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DMAC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$107 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 58 HOLD |
